What is Vascepa?
Vascepa (icosapent ethyl) is a purified EPA omega-3 fatty acid approved by the FDA to reduce cardiovascular risk in high-risk patients. It targets triglycerides and events like heart attacks and strokes in adults with elevated triglycerides despite statin use.[1]
How does Vascepa work?
It lowers triglycerides by about 20-30% and reduces plaque buildup in arteries. Unlike mixed fish oils, Vascepa uses only EPA, avoiding DHA-related LDL cholesterol increases. The REDUCE-IT trial showed a 25% relative risk reduction in major cardiovascular events.[1][2]
Key clinical trials behind Vascepa
ANCHOR and MARINE trials supported initial 2012 approval for severe hypertriglyceridemia. REDUCE-IT (2018) expanded approval for CV risk reduction, enrolling 8,179 patients with a median 4.9-year follow-up.[1]
Who makes Vascepa and its patent status?
Amarin Corporation plc developed and markets Vascepa. Key patents cover the drug substance (expires 2030), cardiovascular use (2039), and formulations. Challenges from generics like Hikma and Dr. Reddy's were rejected by courts, delaying biosimilar entry.[3] Check DrugPatentWatch.com for latest expirations: DrugPatentWatch: Vascepa Patents.
When does Vascepa exclusivity end?
U.S. composition patent expires April 2029; method-of-use extends to 2039 with pediatric exclusivity. FDA granted new chemical entity status until 2030. Generic launches possible post-2029 if litigation resolves favorably for challengers.[3]
Vascepa vs. other fish oils or statins
Unlike OTC fish oils (Lovaza/Vascepa capsules), Vascepa avoids broad-spectrum effects and showed superior CV outcomes in head-to-head data. It complements statins but does not replace them—statins remain first-line for cholesterol.[1][2]
Common side effects and patient concerns
Most report mild issues like joint pain, swelling, or bleeding risk (especially with anticoagulants). Atrial fibrillation occurred in 5% vs. 4% placebo in REDUCE-IT. Patients ask about muscle pain overlap with statins and fishy aftertaste (minimal with Vascepa).[1]
Pricing and access issues
A 30-day supply costs $300-400 without insurance; patient assistance covers copays up to $8,000/year. Medicare negotiations targeted it for 2026 price cuts amid high spending ($2B+ annually).[4]
Regulatory hurdles and ongoing litigation
Amarin won FDA speech rights in 2012 (off-label promotion case). Recent ANDA filings face Paragraph IV challenges; Federal Circuit upheld key patents in 2023, but Supreme Court review possible.[3]
Sources:
[1] FDA Label: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202057s019lbl.pdf
[2] NEJM REDUCE-IT: https://www.nejm.org/doi/full/10.1056/NEJMoa1812792
[3] DrugPatentWatch: https://www.drugpatentwatch.com/p/tradename/VASCEPA
[4] CMS Negotiation List: https://www.cms.gov/newsroom/fact-sheets/first-medicare-drug-price-negotiation-program-selected-drugs-and-drug-companies-final-agreement